ºñ¡À¦®À¨ˆº¹÷É´ ¦½Ïº¤¨Éº−À§œº¸ñ - APAMED Central

¸¾ì½¦¾−¡¾−Á²©ì¾¸ (2011), ¦½®ñ®êó 02: Îɾ 47 Œ 53¦ó¦÷²ñ− ¸ò©¾´¾ìó ²Éº´£½−½ ŒÎɾ 49¯…−¯ö¸-©É¸¨-µ¾ Dexamethasone 8 mg IV À§í¾Œ -Áì¤ À¯ñ−À¸ì¾ 03 ´œ ÁªÈº¾¡¾−£ö−À¥ñ®®Ò©ó¢›−. ªÒ´¾¥‡¤Ä©É À¥¾½-−Õ-Ä¢-¦ñ−Íñ¤-į-¡¸© À§…¤−Õ-Ä¢-¦ñ−Íñ¤´óìñ¡¦½−½-æ, £¸¾´©ñ− =32 CmH 2 O, ´ó WBC = 135 10 6 /L (100% -Á´È−Lymphocytes), Lactate 8.9 mmol/L, Protein = 42 g/L, ºñ©-ª¾-¦È¸−-ì½¹¸È¾¤-−Õª¾−-Ã−-−Õ-Ä¢-¦ñ−Íñ¤ -Áì½ -Ã−-Àìõº©-Á´È−23/132 mg/dL. °ö−¡¾−¡¸© CT scanner ¢º¤¦½Ïº¤ ²ö®Nodule µøȦ½Ïº¤¯È¼¤¢½Ïñ®À®œº¤§É¾¨ ²Éº´êñ¤´óº¾¡¾−®¸´µøȺɺ´ (»ø®êó 1), ¦È¸−°ö−¦Èº¤Ä³³É¾¯º© ²ö®À¤ö¾Reticular µøÈ¥º´¯º©À®œº¤§É¾¨ (»ø®êó 2).»ø®êó 1.Brain CT:hyper-densenodule atleft temporallobe withsign of perilesionedemathat enhanceswith contrast»ø®êó 2.CXR:Reticularshadowing atthe left apex.ºó¤Ã¦È¯½¹¸ñ©¢º¤£ö−À¥ñ® Áì½ £º®£ö¸, ºó¤Ã¦È °ö−¡¸©−ÕÄ¢¦ñ−¹ìñ¤, »ø®ìñ¤¦ó¯º© Áì½ °ö−¡¸©-¢š¡½-Àê†- ꆲö®-À§œºAFB 1+ Ã−´œêó 5 ¹ìñ¤À¢í¾−º−»¤Ï𠥈¤®‰¤´½ªò¸È¾£ö−À¥ñ®À¯ñ− ºñ¡À¦®À¨ˆº¹÷É´¦½Ïº¤ ¨Éº−À§œº¸ñ−−½Âì¡,¦½−˜−¥‡¤Ä©ÉÀ솴ùɡ¾−¯…−¯ö¸ ©É¸¨µ¾- ¸ñ−−½-Âì¡ 4FDC 3À´ñ©/´œ ¦ö´êö®-¡ñ®-µ¾ Dexamethasone 8 mg IV ê÷¡Å 12 §‰¸-´¤. ´œªÒ-´¾-£ö−-À¥ñ®-À¢í¾- Coma, GCS=5 (M=3+V=1 + E =1).°ö−¡¾−¯ø¡−ÕÄ¢¦ñ−¹ìñ¤©É¸¨²ǿ -¯ø¡ Lowenstein Jensen²ö®-À§œº Mycobacterium tuberculosis Ã−º¾êò©êó 6¹ìñ¤À¥¾½−ÕÄ¢¦ñ−¹ìñ¤Ä¯¡¸© À§…¤-À§õûº©„¤-¡ú¾¸-Á´È−«õ¡¡ñ®µ¾ (Sensitive to) Rifampicin Áì½ Isoniazid. ¥ˆ¤Ä©É¦õ®ªÒùɡ¾−¯…−¯ö¸£ö−À¥ñ® ©É¸¨µ¾¸ñ−−½Âì¡-µøÈ-»¤Ïð Áì½ ¯…−¯ö¸¡¾¨¨½®¿®ñ©£ö−À¥ñ® À¯ñ−À¸ì¾ 37 ´œ ¡Èº−¥½ºº¡Â»¤Ïð.Ã−´œºº¡-»¤Ïð- £ö−-À¥ñ®-¨ñ¤-®Ò-êñ−-Ä©É-¦½ªò-, ®Ò-¦¾´¾©¯¾¡Œ-À¸í¾-Ä©É, ®Ò-¦¾´¾©-ÀÎñ¤-ªó¤-Á¢−Œ-¢¾-. ªÒ´¾ 3 À©õº−- Íñ¤-ùɡ¾−-¯…−¯ö¸-©É¸¨-µ¾-ªÉ¾−-¸ñ−−½-Âì¡ £ö−-À¥ñ®-´ó-º¾¡¾−-©ó-¢›−, ¦¾´¾©-ÀÎñ¤-ªó¤-Á¢−-Œ¢¾-Ä©É-Àìñ¡-−ɺ¨, ÁªÈ¨ñ¤®Ò-¦¾´¾©¯¾¡Œ-À¸í¾ Ä©ÉÁ콨ñ¤-ªÉº¤Ä©É¦õ®ªÒ-¯Éº−-º¾¹¾−-°È¾−-êÒìö¤Ä¯¡½À²¾½º¾¹¾−¥ö−À«ó¤´œê†¡¿ìñ¤¢¼−®ö©ì¾¨¤¾−¹¨Ó−š (¸ñ−êó 11/04/ 2011).²¾¡-¦ö−ê½−¾¸ñ−−½-Âì¡- À¯ñ−-®ñ−¹¾-¦¿-£ñ−-꾤-©É¾−-¦¾ì½-−½-¦÷¡-Ã−-ꉸ-Âì¡ êñ¤-¯½-Àê©-ꆲñ©ê½−¾-Áìɸ -Áì½ ¡¿ìñ¤-²ñ©ê½−¾ -À−ˆº¤-¥¾¡¡¾−À²†´¢›−¢º¤-²½¨¾© HIV/AIDS, £¸¾´-Áº-ºñ©-¢º¤-¯½§¾¡º−-Ã−-ªö¸-À´õº¤, ¡¾−-À£ô−¨É¾¨-ŒÀ©ó−꾤 ¢º¤-¯½§¾¡º−-©¨®Ò´ó²ö´Á©−, -Áì½ ®ñ−¹¾¡¾−-ªÉ¾− (©œ) ¢º¤-À§œº¸ñ−−½Âì¡ ªÒ-µ¾-¯…−¯ö¸ (Garg, 1999). ºñ©ª¾-¡¾−-²ö®-¡ðì½−óÃÏÈ-Á´È−-Áª¡-ªú¾¤-¡ñ−-Ã−-ÁªÈì½-¯½-Àê© À§„− ¯½´¾− 9/100,000£ö− Ã−¯½-Àꩦ½¹½ìñ©-º¾-À´-ìò¡¾ À«ó¤ 110- Œ 165/100000£ö− Ã−-¯½-Àê©-¡¿ìñ¤-²ñ©ê½−¾ (Harries, 1990; Snider andRoper, 1992; Raviglione et al., 1995). -¸ñ−−½-Âì¡- ì½®ö®-¯½¦¾©-¦ø−-¡¾¤- ©¨¦½À²¾½À¨ˆº¹÷É´¦½Ïº¤ºñ¡À¦® ¥¾¡À§œº¸ñ−−½Âì¡ À¯ñ−-»ø®-Á®®-·¤-¢º¤-¸ñ−−½-Âì¡−º¡-¯º©- ê†-»û¾¨-Á»¤-ê†-¦÷©. ´ó¡¾−£¾©-£½-À−ĸÉ-¸È¾ -¯½´¾− 10% ¢º¤-£ö−-À¥ñ®-ê†-À¯ñ−-¸ñ−−½-Âì¡êñ¤Ïö©- Á´È−-´ó-¡¾−-Áª½ªÉº¤ -ì½®ö®-¯½¦¾©-¦ø−-¡¾¤ (Wood and Anderson, 1998) Áì½ Ã−-ꉸ-Âì¡-£¾©-¸È¾-´ó-¯½´¾− 2,000,000 £ö− ê†-À¦¨-§ó¸ò©Ã−ÁªÈ콯ó- ¨Éº−-²½¨¾©-¸ñ−−½-Âì¡ (Dye et al., 1999; Corbett et al., 2003).Ã−-¯½Àê©ì¾¸ ºñ©ª¾-¡¾−-À¡ó©-²½¨¾©-ÃÏÈ Áì½ ºñ©ª¾-§÷¡-§÷´-¢º¤-²½¨¾©-¸ñ−−½-Âì¡-¯º© -£¾©-¸È¾-´ó¯½´¾− 151 Áì½ 289£ö− ªÒ 100,000 £ö−, ª¾´-ì¿©ñ® (Arnadottir et al., 2001).¦È¸−ªö¸Àì¡ ¡¾−À¯ñ−²½¨¾©¸ñ−−½Âì¡−º¡¯º© ©¨¦½À²¾½ºñ¡À¦®À¨ˆº¹÷É´¦½Ïº¤¨Éº−À§œº¸ñ−−½Âì¡ Ã−쾸À»ö¾¨ñ¤®Ò»øÉĩɵȾ¤¥½Á¥É¤. ¥¾¡¯½¦ö®¯½¡¾− 꾤£ùó−ò¡¢º¤Á²©Ïðµøú»¤Ïð²ö®¸È¾ ºñ¡À¦®À¨ˆº¹÷É´¦½Ïº¤ ¨Éº−À§œº¸ñ−−½Âì¡ À¯ñ−²½¨¾©ê†²ö®À¹ñ−À윺¨Ä©ÉÀ§„−¡ñ− ÁªÈ¡¾−®‰¤´½ªò²½¨¾© Áì½ ¡¾−¯…−¯ö¸ ´ñ¡¥½§ñ¡§É¾ ©¨¦½À²¾½¡¾−